54gene

African genomics research.

Epitaph

“Here lies 54gene. It set out to build the world's largest library of African DNA and briefly thrived on COVID testing. When that revenue faded, a costly diagnostics expansion drained the cash faster than three CEOs could refill it. The biobank outlived the company.”

Overview

Born: 2019 (Year)
Died: September 2023 (Month)
Lifespan: 5 years
Fate: Shut down
Headquarters: 🇳🇬 Nigeria
Category: Health Tech
Stage at death: Series B
Primary cause: Funding or runway
Contributing causes: Execution, Founder or team, Business model or unit economics

Death certificate

Timeline

201954gene founded
Abasi Ene-Obong launches Nigerian genomics startup to build an African DNA database
April 2020$15M raise
54gene raises $15M led by Adjuvant Capital
August 2022Layoffs and pay cuts
About 30% of staff laid off and leadership salaries cut amid cash crunch
October 2022CEO resigns
Co-founder Abasi Ene-Obong steps down as CEO two months after layoffs
July 2023Wind-down begins
Company starts winding down operations, per CEO Ron Chiarello
September 2023Shutdown confirmed
54gene ceases operations after raising $45M total, website taken down.

Autopsy report

Why did 54gene shut down?

54gene, a Nigerian genomics/health-tech startup that had raised $45M across three rounds, shut down in September 2023 after months of leadership turmoil, unpaid creditors and failed fundraising, following aggressive spending on diagnostics expansion (Seven River Labs) that did not pay off.

What 54gene attempted

Build a large database of African DNA/genomics research and diagnostics company, later expanding into COVID-19 testing and a diagnostics network (Seven River Labs).

What worked

Raised $45M across three funding rounds and generated roughly $20M in revenue from COVID-19 testing at its peak.

Early warning signs

Leadership pay cuts (from $330,000 to $175,999), roughly 30% layoffs by mid-2022, CEO resignation in October 2022, three CEO changes within one year, and mounting unpaid creditors and legal disputes.

What happened

After COVID-testing revenue declined, 54gene's capital-intensive genomics operations and aggressive Seven River Labs diagnostics expansion drained cash; the company cut salaries and laid off about 30% of staff in 2022, co-founder and CEO Abasi Ene-Obong resigned in October 2022, and after further leadership changes and failed fundraising attempts the company began winding down in July 2023, ceasing operations by September 2023 and seeking buyers for its biobank assets.

Lessons for future builders

Building a capital-intensive research business on a temporary revenue spike leaves nothing when the spike passes. Separate one-off pandemic income from the long-term plan, and size expansion to durable demand and secured funding, not peak cash.